Fort Washington Investment Advisors Adds $3M in CVS Health Corporation ($CVS)

Fort Washington Investment Advisors raised its CVS Health stake by 3.7%, adding 26,818 shares.

Editorial illustration for CVS Health Corporation (CVS)

Key Points

  • Fort Washington Investment Advisors increased its CVS Health stake by 26,818 shares, boosting its position by 3.7% to 752,007 shares valued at $76.7 million.
  • CVS Health shares are trading near $101.96 with a market cap of $128.5 billion, a forward P/E of 12.02, and a 52-week range of $58.5 to $102.77.
  • Insiders, including EVP Amy Compton-Phillips, sold shares recently, while analysts like Mizuho maintained a 'buy' rating with a $115 target.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Fort Washington Investment Advisors boosted its position in CVS Health Corporation (NYSE:CVS) by 3.7% during the first quarter of 2026. According to the latest Form 13F filing with the SEC, the firm added 26,818 shares, bringing its total holdings to 752,007 shares valued at approximately $76.7 million.

13F track record

Fort Washington Investment Advisors vs. the S&P 500

YTD return +8.34% hypothetical
All-time return +99.47% S&P 500 +85.58%
vs. S&P 500 +13.89% ahead of the index

Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.

What Changed in Fort Washington Investment Advisors' CVS Health Position

Fort Washington Investment Advisors' decision to increase its stake in CVS Health reflects a positive outlook on the healthcare giant. The firm now holds 752,007 shares, up from 725,189 shares previously, with the additional shares valued at around $76.7 million.

Other Institutional Activity in CVS Health

Other major funds also adjusted their positions in CVS Health. BlackRock, Inc. grew its holdings by 4,925,379 shares, ending with 125,919,853 shares worth about $9.04 billion. Vanguard Capital Management LLC now holds 82,650,076 shares valued at $5.94 billion, having added the same number of shares. Capital World Investors increased its position by 9,585,731 shares to 77,248,642 shares, valued at $5.55 billion. Meanwhile, State Street Corp reduced its holdings by 861,562 shares, bringing its total to 59,322,181 shares worth $4.26 billion. Dodge & Cox also trimmed its stake by 10,729,872 shares to 51,780,116 shares, valued at $3.72 billion.

CVS Health Corporation Stock Up 9.5%

Shares of CVS Health (NYSE:CVS) are trading near $101.96. The company has a market cap of $128.5 billion, a P/E ratio of 44.16, and a forward P/E of 12.02. Its beta is 0.623, indicating relatively low volatility. The stock's 52-week range is between $58.5 and $102.77, with a 50-day moving average of $87.39 and a 200-day moving average of $79.83.

Year to date

$CVS stock price

Daily closing prices, year to date. Not investment advice.

Recent Earnings

CVS Health reported revenue of $405.6 billion, reflecting a growth of 6.1%. The company achieved an earnings per share (EPS) of $2.28. It has a net margin of 0.723% and a return on equity (ROE) of 3.75%. The next earnings report is expected on July 30, 2026.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

B+ 81/100

Reported May 6, 2026

  1. Forward outlook

    11 analysts raised price targets.

  2. EPS & revenue

    EPS beat estimates by 15.8%. Revenue beat estimates by 4.6%.

  3. Profit surprise

    EBITDA beat by 15 percent. Operating income beat by 4 percent.

  4. Pre-earnings setup

    Bar was high, analysts already very bullish.

  5. Analyst signal

    11 target raises.

  6. Earnings quality

    Operating margin up 1.1 points. Positive free cash flow.

Earnings Call Summary

CVS delivered a strong first quarter with $100.4 billion in revenue, up 6 percent year over year, and earnings per share of $2.57, beating consensus by 36 cents. The Aetna health insurance business showed major improvement with operating income up 1 billion dollars year over year and a better medical benefit ratio. Pharmacy sales grew 3 percent at existing stores driven by strong prescription volume increases. Management is focused on affordability, reducing friction in the health system, and launching a new consumer app called Health100 powered by artificial intelligence.

Guidance CVS raised full year earnings guidance to $7.30 to $7.50 per share, up from $7.00 to $7.20. They expect at least $405 billion in revenue for the year. Operating cash flow guidance improved to at least $9.5 billion.

Good report. The company beat and showed some forward improvement, with a few meaningful caveats.

Dividend

CVS Health offers an annual dividend rate of $2.66, yielding 2.64%. The dividend payout ratio stands at 116.67%.

Insider Buying and Selling at CVS Health Corporation

Several insiders sold shares of CVS Health recently. On May 31, 2026, Amy Compton-Phillips, EVP and Chief Medical Officer, sold 7,618 shares at an average price of $90.98. Brian Newman, EVP and CFO, also sold 2,478 shares at the same price on the same day. Fernando Aguirre sold 1,563 shares at $93.50 and 30,437 shares at $93.78 on May 21. Larry Robbins sold 370,462 shares at $93.45 and 378,000 shares at $93.31 on May 21.

Analysts Set New Price Targets

Analysts remain optimistic about CVS Health. On June 8, 2026, Mizuho maintained a 'buy' rating with a price target of $115. Morgan Stanley also maintained a 'buy' rating with a $111 target on June 4. Other firms like Truist Securities and Barclays maintained 'buy' ratings with targets of $108 and $106, respectively. The consensus among analysts is a 'strong buy' with a mean target price of $104.50.

About CVS Health Corporation

CVS Health Corporation, based in Woonsocket, Rhode Island, provides health solutions in the U.S. It operates through segments like Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness. The company offers a range of insurance products and services, pharmacy benefit management, and sells prescription and over-the-counter drugs. Led by CEO J. David Joyner, CVS Health employs about 219,000 people.

Bottom Line

Fort Washington Investment Advisors' increased stake in CVS Health showcases investor confidence in the company's prospects. The 13F filing reflects holdings as of the first quarter of 2026, and may not indicate the firm's current position. Investors track such filings for insights into institutional sentiment, but they represent past, not current, holdings.

Get CVS Health Corporation alerts

New 13F filings, insider trades, and analyst moves on $CVS, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.